Abstract
5025 Background: PI3K pathway activation is common in mCRPC. BKM120 (buparlisib) is an oral, pan-class I PI3 kinase inhibitor. Preclinical data demonstrated a reciprocal feedback loop between PI3K ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have